➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
AstraZeneca
Medtronic
Baxter
Boehringer Ingelheim

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062640

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 062640 describes CEFTAZIDIME, which is a drug marketed by Acs Dobfar, Aurobindo Pharma Ltd, Wockhardt, B Braun, and Baxter Hlthcare, and is included in six NDAs. It is available from two suppliers. Additional details are available on the CEFTAZIDIME profile page.

The generic ingredient in CEFTAZIDIME is ceftazidime sodium. There are seventeen drug master file entries for this compound. Additional details are available on the ceftazidime sodium profile page.
Summary for 062640
Tradename:CEFTAZIDIME
Applicant:Acs Dobfar
Ingredient:ceftazidime
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 062640
Medical Subject Heading (MeSH) Categories for 062640
Suppliers and Packaging for NDA: 062640
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFTAZIDIME ceftazidime INJECTABLE;INJECTION 062640 ANDA Sagent Pharmaceuticals 25021-127 25021-127-20 25 VIAL in 1 CARTON (25021-127-20) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL
CEFTAZIDIME ceftazidime INJECTABLE;INJECTION 062640 ANDA Sagent Pharmaceuticals 25021-127 25021-127-66 25 VIAL in 1 CARTON (25021-127-66) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength500MG/VIAL
Approval Date:Nov 20, 1985TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL
Approval Date:Nov 20, 1985TE:APRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/VIAL
Approval Date:Nov 20, 1985TE:APRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.